Physician profile
John C Welch
NPI 1528178886
$2,298.79
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,326 · 2020: $290 · 2021: $463 · 2022: $202 · 2023: $17.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $298.70 | 2019-2021 | |
| Novo Nordisk INC | $288.88 | 2019-2022 | |
| Lilly USA, LLC | $185.28 | 2019-2022 | |
| Abbvie INC. | $181.72 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $176.82 | 2019-2022 | |
| Glaxosmithkline, LLC. | $153.30 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $148.01 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $113.50 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.04 | 2019-2021 | |
| Astellas Pharma US INC | $100.89 | 2019-2021 | |
| Pfizer INC. | $77.10 | 2019-2020 | |
| Amarin Pharma, INC. | $75.94 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.25 | 2019-2022 | |
| Allergan, INC. | $43.21 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.79 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $31.12 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $28.72 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.74 | 2019 | |
| Neos Therapeutics, LP | $18.92 | 2019 | |
| Radius Health, INC. | $17.70 | 2019 | |
| Dexcom, INC. | $17.58 | 2023 | Dexcom G6 Transmitter |
| Ironshore Pharmaceuticals INC. | $17.36 | 2022 | |
| Merck Sharp & Dohme LLC | $15.19 | 2022 | |
| Mylan Specialty L.P. | $14.05 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.85 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.08 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.71 | 2021 | |
| Grifols USA, LLC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Welch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.